<DOC>
	<DOCNO>NCT01769170</DOCNO>
	<brief_summary>The purpose study compare effectiveness CMX001 placebo prevention CMV infection stem cell transplant patient CMV start treatment CMX001 .</brief_summary>
	<brief_title>A Study Safety Efficacy CMX001 Prevention Cytomegalovirus ( CMV ) Infection CMV-seropositive ( R+ ) Hematopoietic Stem Cell Transplant Recipients</brief_title>
	<detailed_description />
	<criteria>Subjects adult allogeneic HSCT recipient age â‰¥ 18 yearsold ( applicable , per local law ) CMV seropositive transplantation CMV viremia negative posttransplant . Subjects positive CMV viremia test time transplant First Dose Day ( FDD ) . Subjects hypersensitivity ( renal dysfunction eye disorder ) CDV CMX001 excipients . Subjects receive antiCMV therapy investigational antiCMV drug time posttransplant . Subjects antiCMV vaccine time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CMV</keyword>
	<keyword>Hematopoietic Stem Cell Transplant Recipients</keyword>
	<keyword>CMV seropositive</keyword>
</DOC>